Should I buy or sell Eyenovia stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYEN shares. View EYEN analyst ratings or view top-rated stocks .

What is Eyenovia's stock price target for 2024?

3 brokerages have issued twelve-month target prices for Eyenovia's stock. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,652.5% from the stock's current price. View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts .

How have EYEN shares performed in 2024?

Eyenovia's stock was trading at $2.08 at the beginning of the year. Since then, EYEN stock has decreased by 72.6% and is now trading at $0.5706. View the best growth stocks for 2024 here .

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 46.2% from the March 15th total of 3,570,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 5.1 days. View Eyenovia's Short Interest .

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EYEN earnings forecast .

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). During the same period last year, the company earned ($0.17) earnings per share.

What other stocks do shareholders of Eyenovia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Vaxart (VXRT) , Axsome Therapeutics (AXSM) , Aldeyra Therapeutics (ALDX) , Leap Therapeutics (LPTX) , Trevena (TRVN) , Albireo Pharma (ALBO) , BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS) .

When did Eyenovia IPO?

Eyenovia (EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EYEN

Eyenovia (EYEN) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free EYEN Stock Alerts

$0.57

+0.04 (+7.54%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.52
▼
$0.59
50-Day Range: $0.53
▼
$2.37
52-Week Range: $0.50
▼
$5.85

Volume: 1.37 million shs
Average Volume: 1.50 million shs
Market Capitalization: $27.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Eyenovia alerts:

Eyenovia MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,652.5% Upside
$10.00 Price Target
Short Interest: Bearish
11.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$176,433 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.89) to ($1.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.76 out of 5 stars

Medical Sector

838th out of 911 stocks

Pharmaceutical Preparations Industry

379th out of 413 stocks

3.5

Analyst's Opinion

Consensus Rating
Eyenovia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Eyenovia has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.01% of the outstanding shares of Eyenovia have been sold short.
Short Interest Ratio / Days to Cover
Eyenovia has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Eyenovia has recently increased by 46.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Eyenovia does not currently pay a dividend.
Dividend Growth
Eyenovia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EYEN.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Eyenovia this week, compared to 2 articles on an average week.
Search Interest
Only 29 people have searched for EYEN on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.
MarketBeat Follows
8 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $176,433.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Eyenovia is held by insiders.
Percentage Held by Institutions
Only 25.84% of the stock of Eyenovia is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Eyenovia are expected to decrease in the coming year, from ($0.89) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eyenovia is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eyenovia is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eyenovia has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Eyenovia Stock (NASDAQ:EYEN)

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

EYEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EYEN Stock News Headlines

March 30, 2024 | insidertrades.com

Stuart M. Grant Acquires 100,000 Shares of Eyenovia, Inc. (NASDAQ:EYEN) Stock

March 21, 2024 | insidertrades.com

Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Acquires $61,500.00 in Stock

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | msn.com

Eyenovia (EYEN) Price Target Decreased by 24.29% to 7.21

April 10, 2024 | investing.com

Eyenovia explores strategic alternatives amid new product developments

April 8, 2024 | marketwatch.com

Eyenovia Shares Fall More Than 14% After Company Says It Is Exploring Sale

April 8, 2024 | marketwatch.com

Eyenovia Explores Options, Including Potential Sale

April 8, 2024 | globenewswire.com

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | reuters.com

Eyenovia Inc

April 4, 2024 | msn.com

Lenz Therapeutics’ Eye Drop Helps Improve Vision in Late-Stage Study

April 3, 2024 | globenewswire.com

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

March 20, 2024 | seekingalpha.com

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

March 19, 2024 | finanznachrichten.de

Eyenovia, Inc.: Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 19, 2024 | markets.businessinsider.com

Eyenovia’s Strategic Commercial Synergy and Growth Potential Reinforce Buy Rating

March 19, 2024 | finance.yahoo.com

Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript

March 19, 2024 | finance.yahoo.com

Q4 2023 Eyenovia Inc Earnings Call

March 18, 2024 | benzinga.com

Recap: Eyenovia Q4 Earnings

March 18, 2024 | investorplace.com

EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023

March 18, 2024 | markets.businessinsider.com

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 18, 2024 | globenewswire.com

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 17, 2024 | msn.com

Eyenovia Q4 2023 Earnings Preview

March 13, 2024 | globenewswire.com

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

March 11, 2024 | markets.businessinsider.com

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

March 11, 2024 | globenewswire.com

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

March 6, 2024 | markets.businessinsider.com

Eyenovia, Formosa Gets FDA Approval For Clobetasol Propionate Ophthalmic Eye Drops

March 6, 2024 | markets.businessinsider.com

Eyenovia’s Strategic Expansion: Dual Product Offering Enhances Market Position

See More Headlines

Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EYEN
CUSIP: N/A
CIK: 1682639
Web: www.eyenoviabio.com
Phone: (917) 289-1117
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $12.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +1,652.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,260,000.00
Net Margins: N/A
Pretax Margin: -719,857.44%
Return on Equity: -213.33%
Return on Assets: -89.16%

Debt

Debt-to-Equity Ratio: 1.00
Current Ratio: 2.17
Quick Ratio: 2.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 2.85

Miscellaneous

Outstanding Shares: 47,390,000
Free Float: 43,690,000
Market Cap: $27.04 million
Optionable: Optionable
Beta: 1.64

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Tsontcho Ianchulev M.D. (Age 49)
M.P.H., MPH, Co-Founder & Executive Chairman
Comp: $920.87k
Mr. Michael M. Rowe (Age 62)
CEO & Director
Comp: $750.01k
Mr. John P. Gandolfo CPA (Age 63)
CFO & Secretary
Comp: $598.39k
Mr. Bren Kern (Age 42)
COO & Corporate VP
Alexander Lobo
Investor Contact

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EYEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings or view top-rated stocks.
What is Eyenovia's stock price target for 2024?: 3 brokerages have issued twelve-month target prices for Eyenovia's stock. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,652.5% from the stock's current price.
View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts.
How have EYEN shares performed in 2024?: Eyenovia's stock was trading at $2.08 at the beginning of the year. Since then, EYEN stock has decreased by 72.6% and is now trading at $0.5706.
View the best growth stocks for 2024 here.
Are investors shorting Eyenovia?: Eyenovia saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 46.2% from the March 15th total of 3,570,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 5.1 days.
View Eyenovia's Short Interest.
When is Eyenovia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EYEN earnings forecast.

How were Eyenovia's earnings last quarter?: Eyenovia, Inc. (NASDAQ:EYEN) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). During the same period last year, the company earned ($0.17) earnings per share.
What other stocks do shareholders of Eyenovia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Trevena (TRVN), Albireo Pharma (ALBO), BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS).
When did Eyenovia IPO?: Eyenovia (EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
How do I buy shares of Eyenovia?: Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EYEN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial